Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7
Primary Industries
- Drugs
- Disease
- Therapeutic
- Delivery
- Pharmaceuticals
- Nanoparticles
- Diagnostic
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 273416
Licensed Patents means any and all Patent Rights which Licensor Controls in any country of the Territory, having one or more Valid Claims Covering the Licensed Compound or Product in the Field and which are reasonably necessary or useful to research, develop, prepare, make, have made, market, export, have exported, import, use, offer for sale, sell, have sold, distribute, promote, detail or otherwise commercialize a Licensed Compound or Product in the Field in the Territory. Licensed Patents includes the Patent Rights set forth below
U.S. Patent 6312662 – Prodrugs phosphorus-containing compounds
U.S. Patent 6946115 – Prodrugs for phosphorus-containing compounds
U.S. Patent 6752981 – Prodrugs for liver specific drug delivery
Licensed Technology means all HepDirect Technology on the Closing Date or during the Term, which are necessary or useful to research, develop, prepare, make, have made, market, export, have exported, import, use, offer for sale, sell, have sold, distribute, promote, detail or otherwise commercialize a Licensed Compound or Product in the Field in the Territory. By way of clarification, Licensed Technology includes all such HepDirect Technology conceived or acquired in whole or in part by Licnesor on or after the Closing Date including the items set forth in the agreement.
Licensed Compound means all forms of MB6866 as identified (at times known as remofovir and now known as pradefovir) including any complexes, chelates, clathrates, acids, bases, esters, salts, isomers, stereoisomers, enantiomers, pro-drug form, metabolite, hydrate, solvate, polymorph, and crystalline forms thereof, or any Substitute Compound substituted in accordance with Article III, and its various forms including salts and prodrugs.
IPSCIO Record ID: 294260
Product means any human pharmaceutical product in finished pharmaceutical form containing, in whole or as a component, the Licensed Compound.
Licensed Technology means the Licensed Know-How. Licensed Know-How means any Know-How Controlled by Licensor as of the Effective Date or thereafter during the Term relating to the Licensed Compound that is reasonably necessary or useful to research, develop, prepare, make, have made, market, export, have exported, import, use, offer for sale, sell, have sold, distribute, promote, detail or otherwise commercialize a Licensed Compound or Product in the Field in the Territory.
IPSCIO Record ID: 839
Licensor hereby grants to Licensee and its Affiliates an exclusive, royalty-bearing right and license under the MB07133 Technology to make, have made, use, sell, have sold, import and export MB07133 in the HCC Field in China and under the HepDirect Technology to make, have made, use, sell, have sold, import and export other HCC Compounds and HCC Products in the HCC Field in China.
Licensor hereby grants to Licensee and its Affiliates a non-exclusive, royalty-bearing right and license under the HepDirect Technology to Develop, make, have made, use, sell, have sold, import and export HepB Compounds and HepB Products in the HepB Field and HCC Compounds and HCC Products in the HCC Field, each in the Territory.
HCC Compound means any Licensed Compound other than MB07133 developed using or incorporating HepDirect Technology, which is selected by Chiva for Development and/or commercialization by Chiva in the HCC Field.
HCC Product means any product intended for use in the HCC Field that contains a HCC Compound, whether alone or in combination with another active pharmaceutical ingredient, the manufacture, use, sale, offer for sale, import or export of which would, but for the rights granted, infringe a Valid Claim.
HepB Compound means any Licensed Compound other than Pradefovir developed using or incorporating HepDirect Technology, which is selected by Chiva for use in the HepB Field.
HepB Product means any product intended for use in the HepB Field that contains a HepB Compound, whether alone or in combination with another active pharmaceutical ingredient, the manufacture, use, sale, offer for sale, import, or export of which would, but for the rights granted, infringe a Valid Claim.
HepDirect means the proprietary prodrug technology that targets delivery of drugs to the liver by using compositions, and methods of making and using the same, of any and all.
The Licensor is entitled to receive a portion of any sublicensing revenue generated from sublicensing of collaboration compounds to third parties in a major world market.
The Licensee is obligated to develop these programs to address the high unmet medical need in China’s fast growing pharmaceutical market. The Chinese government is offering financial support to pharmaceutical companies like the Licensee who can develop innovative therapies in China for public health needs such as infectious disease and oncology.
HCC Field means the treatment or prevention of hepatocellular carcinoma in humans.
HepB Field means the treatment or prevention of hepatitis B virus infection in humans.
IPSCIO Record ID: 233451
The initial compound means the compound ICA-17043 having the molecular structure set forth and any hydrates, anhydrides, solvates, salts, esters, isomers, prodrugs, metabolites or polymorphs thereof.
The Product means a pharmaceutical product that contains, incorporates or is comprised of the Compound, whether in development or approved by any Regulatory Authority, including all formulations, line extensions and modes of administration thereof.
The Licensor Patents means all Patents, other than CMCC Patents, Controlled by Licensor as of the Effective Date or during the Term, that, absent rights thereunder, would be infringed by the Development, Manufacture, formulation, use, distribution, importation, sale, or offer for sale of Compound or Product, including without limitation any such Patents claiming the composition of matter or the use of Compound or Product or any Improvements thereto.
Licensors know-how means all Information, except for CMCC Know-How, that Licensor Controls as of the Effective Date or during the Term.
IPSCIO Record ID: 273379
Licensor grants a worldwide, non-exclusive license to the Licensor Trademark, solely for the purpose of fulfilling Licensees obligations in relation to this Agreement.
Other Compound means diazepam (7-chloro-l-methyl-5-phenyl-l ,3-dihydro-2H-1 ,4- benzodiazepin-2-one). including all salts, esters, complexes, chelates, hydrates, isomers, stereoisomers, crystalline forms, amorphous forms, prodrugs (including all compounds that are metabolized or dissolve into the same active moiety in the body), solvates, metabolites/metabolic precursors, and pegylated form thereof.
Product means the nasal formulation of Product Intermediate incorporated or filled into a Device.
Buccal Formulation means formulations of Product Intermediate for administration by placing in the mouth for absorption through the cheek, the gum or the upper or lower inside lip without swallowing, achieved by means of a muco adhesive, including but not limited to any specific formulation that may be selected for commercialization.
Field means the use as a prescription or over-the-counter pharmaceutical product in humans, specifically excluding diagnostic use.
Licensee acquired global rights to a novel nasal lorazepam formulation for the treatment of emergency seizures in epilepsy patients.
IPSCIO Record ID: 239024
Licensor possesses significant expertise in the field of antiinflammatory therapeutics, and dersalazine represents the culmination of years of internal research.
Dersalazine is a new chemical entity that combines a well-known anti-inflammatory agent, 5-ASA, with a novel potent agent that acts as a PAF antagonist and an inhibitor of key interleukin cytokines to achieve a synergistic therapeutic effect when compared to the activities of each component separately. Chemical cleavage of dersalazine by colonic bacteria releases the two active compounds for the topical treatment of inflammation in the colon. The 5-ASA molecule contained in dersalazine has known antioxidant properties which may ameliorate the deleterious inflammatory effects ascribed to the overproduction of free radicals.
IPSCIO Record ID: 211925
The product is the proprietary compound known as ORI-9020. ORI-9020 means ORI-9020 and its analogs, the chemical composition of which are described in the patent and any prodrug, metabolite, analog, salt, hydrate, solvate, polymorph, chimeric or inverted chimeric or isomer of ORI-9020.
